Mercer Global Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-10,631
Closed -$257K – 3898
2026
Q2
$257K Sell
10,631
-1,475
-12% -$27.9K ﹤0.01% 2979
2026
Q1
$199K Buy
12,106
+1,135
+10% +$21.7K ﹤0.01% 2840
2025
Q4
$172K Buy
+10,971
New +$148K ﹤0.01% 2611

Other funds holding GLUE

Mercer Global Advisors's GLUE Position: Q3 2026 in Review

Mercer Global Advisors sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 10,631 shares — an estimated $257K sold.

Mercer Global Advisors first reported a position in GLUE in Q4 2025 and held it in 3 quarters. The position peaked at $257K in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Mercer Global Advisors reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Mercer Global Advisors sold 10,631 Monte Rosa Therapeutics shares in Q3 2026, an estimated $257K.
  • Mercer Global Advisors first reported a position in Monte Rosa Therapeutics in Q4 2025 and held it in 3 quarters.
  • Mercer Global Advisors's Monte Rosa Therapeutics position peaked at $257K in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.